

**UNITED STATES SECURITIES AND EXCHANGE  
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES**

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Cline Christopher R.</u>  (Last) (First) (Middle) <u>C/O TRAVERE THERAPEUTICS, INC.</u> <u>3611 VALLEY CENTRE DRIVE, STE 300</u>  (Street) <u>SAN DIEGO CA 92130</u>  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>09/01/2022</u>	3. Issuer Name and Ticker or Trading Symbol <u>Traverse Therapeutics, Inc. [ TVTX ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Financial Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	28,723	D	

**Table II - Derivative Securities Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Option (Right to Buy)	(1)	08/10/2024	Common Stock	40,000	12.51	D	
Employee Stock Option (Right to Buy)	(1)	06/30/2025	Common Stock	15,000	32.49	D	
Employee Stock Option (Right to Buy)	(1)	05/18/2026	Common Stock	20,000	16.23	D	
Employee Stock Option (Right to Buy)	(1)	05/16/2027	Common Stock	20,000	17.44	D	
Employee Stock Option (Right to Buy)	(1)	05/09/2028	Common Stock	12,500	25.25	D	
Employee Stock Option (Right to Buy)	(2)	05/08/2029	Common Stock	10,000	17.96	D	
Employee Stock Option (Right to Buy)	(3)	01/30/2030	Common Stock	12,500	15.46	D	
Employee Stock Option (Right to Buy)	(4)	01/20/2031	Common Stock	16,250	26.88	D	
Employee Stock Option (Right to Buy)	(5)	01/30/2032	Common Stock	17,500	27.5	D	

**Table II - Derivative Securities Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Option (Right to Buy)	(6)	04/09/2032	Common Stock	5,000	28.55	D	

**Explanation of Responses:**

1. The stock option is fully vested and exercisable.
2. One-fourth of the shares subject to the stock option vested and become exercisable on May 9, 2020, and the remaining shares vest in 36 equal monthly installments thereafter.
3. One-fourth of the shares subject to the stock option vested and become exercisable on January 31, 2021, and the remaining shares vest in 36 equal monthly installments thereafter.
4. One-fourth of the shares subject to the stock option vested and became exercisable on January 21, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
5. One-fourth of the shares subject to the stock option will vest and become exercisable on January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.
6. One-fourth of the shares subject to the stock option will vest and become exercisable on April 10, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.

**Remarks:**

/s/ Elizabeth E. Reed,  
Attorney-in-Fact

09/01/2022

\*\* Signature of Reporting  
Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

POWER OF ATTORNEY

Know all, by these presents, that the undersigned hereby constitutes and appoints each of Elizabeth E. Reed and Sandra Calvin, signing individually, the undersigned's true and lawful attorneys-in fact and agents to:

(1) execute for and on behalf of the undersigned, an officer, director or holder of 10% or more of a registered class of securities of Traverre Therapeutics, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact shall no longer be employed by the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 11th day of August, 2022.

/s/ Christopher R. Cline